The First Affiliated Hospital of Soochow University clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 258 studies whose lead sponsor is The First Affiliated Hospital of Soochow University. 149 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the The First Affiliated Hospital of Soochow University studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Where
- China
- 238
Focus areas
Conditions The First Affiliated Hospital of Soochow University leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 258. Browse all 258 →
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingNCT07159620Phase 2
- BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaRecruitingNCT07854652Phase 1
- CMOP±R in the Treatment of Untreated Non-Hodgkin's LymphomaRecruitingNCT06486337Phase 2
- VA vs DA for Newly Diagnosed Hig-risk AMLRecruitingNCT05939180Phase 2/3
- PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCTRecruitingNCT05772273Not applicable
- U69-CART-Cells For R/R T-ALLRecruitingNCT07350863Phase 1
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 2
- Safety and Feasibility of FMT for Immune Recovery After HSCTNot yet recruitingNCT07755319Phase 1/2
- Venetoclax Combined With Azacitidine for Consolidation Therapy in AMLRecruitingNCT07425782Phase 2
- VA Consolidation in Intermediate-Risk AMLRecruitingNCT07672262Phase 2
- Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and PrognosisRecruitingNCT07670130
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Phase 4
- A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07599423Phase 2
- CMV-CMI in csCMVi After HSCTRecruitingNCT07688759
- Younger vs. Older Donors in Allo-HSCT: TTENot yet recruitingNCT07666568
- Cousin vs. Sibling Donors in Haplo-HSCTNot yet recruitingNCT07662382
- Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled StudyNot yet recruitingNCT07655674Not applicable
- Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.RecruitingNCT07074496Early Phase 1
- Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple MyelomaRecruitingNCT07652138Phase 1
- Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast CancerRecruitingNCT07647263Phase 2
- RN1201 Injection in the Treatment of Antibody-Mediated DiseasesRecruitingNCT07072247Phase 1
- SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07575412Phase 2
- VA Induction and Bridging Transplantation for Hypoplastic/Secondary AMLNot yet recruitingNCT07635485Not applicable
- Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingNCT07635511Phase 3
- FMT in Transplant-related Gastrointestinal MucositisEnrolling by invitationNCT07622849
- FMT in Gut aGVHD TreatedRecruitingNCT03148743
- Efficacy and Safety of Auto-FMT in Preventing aGVHDRecruitingNCT04745221Not applicable
- Romiplostim for Oral TPO-RA Resistant ITPRecruitingNCT07612319Not applicable
- U96-CAR-T-Cells For R/R B-ALLNot yet recruitingNCT07511426Phase 1
- Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell LymphomaNot yet recruitingNCT07609446
- Effect of VR-MBCT in Chronic Nonspecific Low Back PainRecruitingNCT07589790Not applicable
- VABu Conditioning in Elderly AML HSCTRecruitingNCT07583888Phase 2/3
- Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical TrialRecruitingNCT07581756Not applicable
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruitingNCT07573670Phase 2
- Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07564453Phase 2
- Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
- SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07562568Phase 2
- Peripheral Blood KIT-D816V Mutation in Adult Systemic MastocytosisRecruitingNCT07562542
- A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCTRecruitingNCT07559695
- The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single CenterRecruitingNCT07552285
- AI Model for Early Gastric Cancer Diagnosis Using Endoscopic ImagingRecruitingNCT07551466
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute LeukemiaRecruitingNCT06816134Phase 2
- A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly PatientsRecruitingNCT07500753Not applicable
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AARecruitingNCT07400341Phase 2
- Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT PatientsRecruitingNCT07400328Phase 2
- A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic AnemiaRecruitingNCT07499284Not applicable
- Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingNCT07499271Phase 2
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Phase 2
- MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingNCT07463651Phase 3